Jeffrey H. Hager

Ideaya Biosciences (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index4.4kcitations89works6.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(36), Prostate Cancer Treatment and Research(28), Histone Deacetylase Inhibitors Research(16), Protein Degradation and Inhibitors(10), Computational Drug Discovery Methods(9)

Publications89 total

Author Correction: A multilineage screen identifies actionable synthetic lethal interactions in human cancers
Nature Genetics·2025· 1 citedOpen Access
A multilineage screen identifies actionable synthetic lethal interactions in human cancers
Nature Genetics·2024· 11 citedOpen Access
Data from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Data from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Supplementary Methods, Figure Legend, Tables 1 - 6 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Supplementary Methods, Figure Legend, Tables 1 - 6 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Supplementary Figures 1 - 11 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Supplementary Figures 1 - 11 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
2023Open Access
Supplementary Fig. S2 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S2 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Methods from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Methods from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Fig. S1 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table S1 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Data from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Table S1 from KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>
2023Open Access
Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
page 1 of 5Next →

Frequent Co-authors

James D. Joseph(22), John Sensintaffar(20), Céline Bonnefous(19), Beatrice Darimont(19), Peter J. Rix(18), Anna Aparicio(17), Richard A. Heyman(15), Nicholas D. Smith(13), Eric D. Bischoff(11), Gang Shao(11), Jing Qian(11), Nhin Lu(11), Mehmet Kahraman(11), Steven P. Govek(11), Kate Grillot(10), Douglas Hanahan(10), Andiliy Lai(10), Johnny Nagasawa(10), Rene Prudente(10), Karensa Douglas(9)